Search Results - "Chehrazi-Raffle, A."

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California.

Authors: Salgia, Nicholas J. Chehrazi-Raffle, Alexander Hsu, JoAnn et al.

Source: Cancer Medicine. Aug2021, Vol. 10 Issue 16, p5671-5680. 10p.

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Authors: Choueiri, Toni K Albiges, Laurence Barthélémy, Philippe et al.

Source: Lancet. Oct2024, Vol. 404 Issue 10460, p1309-1320. 12p.

Subjects: Vascular endothelial growth factor receptors, Immune checkpoint inhibitors, Clinical trials, Protein-tyrosine kinase inhibitors, Renal cell carcinoma, Progression-free survival

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.

Authors: Gong, Jun Chehrazi‐Raffle, Alexander Placencio‐Hickok, Veronica et al.

Source: Clinical & Translational Medicine. Dec2019, Vol. 8 Issue 1, p1-14. 14p.

Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.

Authors: Chehrazi-Raffle, Alexander Muddasani, Ramya Dizman, Nazli et al.

Source: JCO Precision Oncology. 4/30/2023, p1-9. 9p.

Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.

Authors: Zengin, Zeynep B. Chehrazi-Raffle, Alex Salgia, Nicholas J. et al.

Source: Urologic Oncology. Feb2022, Vol. 40 Issue 2, p25-36. 12p.

Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses.

Authors: Chehrazi-Raffle, Alexander Malhotra, Jasnoor Salgia, Sabrina et al.

Source: JCO Precision Oncology. 5/10/2021, Vol. 5, p557-560. 4p.

Disparities in Outcomes in Latino Subpopulations with Localized Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Analysis.

Authors: Jaime-Casas, Salvador Barragan-Carrillo, Regina Kothari, Anjaney et al.

Source: Cancers. Mar2026, Vol. 18 Issue 6, p1035. 14p.

This result is not displayed to guests.
Login for full access.

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma.

Authors: Chehrazi-Raffle, Alexander Dorff, Tanya B. Pal, Sumanta K. et al.

Source: Cancers. 2/15/2021, Vol. 13 Issue 4, p889-889. 1p.

Lenvatinib and Pembrolizumab Move the Needle for Most Non–clear-cell Renal Cell Carcinomas, Yet Rare Histologies Still Lag Behind.

Authors: Dizman, Nazli Ebrahimi, Hedyeh Chehrazi-Raffle, Alexander

Source: European Urology. Dec2025, Vol. 88 Issue 6, p625-627. 3p.

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.

Authors: Gong, Jun Chehrazi-Raffle, Alexander Reddi, Srikanth et al.

Source: Journal for ImmunoTherapy of Cancer. 1/23/2018, Vol. 6, p1-N.PAG. 18p.

Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer.

Authors: Jaime-Casas, Salvador Yip, Wesley Lama, Daniel J. et al.

Source: Cancers. Oct2025, Vol. 17 Issue 19, p3265. 13p.

Toxoplasma gondii Serology and Outcomes After Heart Transplantation: Contention in the Literature.

Authors: Chehrazi-Raffle, A. Luu, M. Yu, Z. et al.

Source: Transplantation Proceedings. Jul2015, Vol. 47 Issue 6, p1949-1953. 5p.

Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care.

Authors: Kuo, Phillip H. Poku, Erasmus Kofi Yamauchi, Dave M. et al.

Source: Journal of Nuclear Medicine Technology. Dec2025, Vol. 53 Issue 4, p300-304. 5p.

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration.

Authors: Abreu de Góes, Vitor Lee, Matthew Zugman, Miguel et al.

Source: JCO Precision Oncology. 5/18/2026, Vol. 10, p1-7. 7p.

Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion.

Authors: Mercier, Benjamin D. Govindarajan, Ameish Castro, Daniela V. et al.

Source: Cancer Medicine. Apr2025, Vol. 14 Issue 7, p1-8. 8p.

1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC).

Authors: Chehrazi-Raffle, A. Muddasani, R. Dizman, N. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1223-S1223. 1p.

Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized.

Authors: Góes, Vitor Li, Yu Jun Chehrazi-Raffle, Alexander

Source: JCO Precision Oncology. 10/15/2025, Vol. 9, p1-2. 2p.

Olaparib Response in a Patient With Platinum-Refractory Germ Cell Tumor Harboring a Somatic BRIP1 Mutation.

Authors: Gismondi, Camila Bobato Lara Agarwal, Ruchi Teixeira, Maria Fernanda Botelho et al.

Source: JCO Precision Oncology. 1/8/2026, Vol. 10, p1-5. 5p.

Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.

Authors: Castro, Daniela V. Prajapati, Sweta R. Feng, Matthew I. et al.

Source: BJU International. Mar2024, Vol. 133 Issue 3, p297-304. 8p.